Home > Resources > Whitepapers > Synthetic Biology: The Future is Now

Synthetic Biology: The Future is Now

May 1, 2016

Biotechnology and specifically Synthetic Biology (SynBio) is evolving at lightning speed. SynBio makes it possible to engineer life from the ground up (allowing the formation of organisms with genetic code (DNA) not found in the natural world) and to redesign existing natural bio systems for life-changing purposes.1 The opportunities are limitless and so are the risks.

Spotlight

Aspetar

Aspetar is the first specialised Orthopaedic and Sports Medicine Hospital in the Gulf region. It provides the highest possible medical treatment for sports-related injuries in a state-of-the-art facility, staffed by some of the world’s leading sports medicine practitioners and researchers. Through the delivery of excellence in sports medicine, physiotherapy, sports science, orthopaedic surgery and rehabilitation, Aspetar services the needs of football and Sports Clubs and Federations throughout the state of Qatar, and regularly services international athletes and professional sportspeople.

OTHER WHITEPAPERS

Improve Your Gene-Editing Success With CRISPR-SNIPER Technology

whitePaper | February 15, 2023

The discovery of both CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) and associated proteins, the Cas nucleases, has revolutionized the field of gene-editing.

THE RNA PLATFORM

whitePaper | May 26, 2022

Exploring biomarkers with the new central dogma. It can be a daunting decision for scientists to know when to focus on DNA, messenger RNA (mRNA), non-coding RNA (ncRNA) or protein biomarkers for routine clinical use, with each exhibiting its own strengths and limitations

Leveraging innovations in plasmid manufacturing to bring advanced therapies to market

whitePaper | December 13, 2022

The global demand for plasmid DNA has increased dramatically in recent years, fueled by a surge in the clinical development of next-generation cell and gene therapy products and more recently by the success of COVID-19 vaccines.

Pioneering Cell and Gene Therapy Solutions From Discovery to the Clinic

whitePaper | April 14, 2020

Your vision is to create revolutionary cell and gene therapies to treat life threatening diseases. Bio-Techne and its family of brands is on this journey with you. As a full-solution ancillary reagent and services provider, we will stand by you, providing flexible and pioneering tools to simplify your workflow. From CAR T cells to pluripotent stem cells, let us help you get your therapy to the patients that need it

T Cell Expansion in Small Scale Bioreactors

whitePaper | October 28, 2022

Adoptive cell therapy (ACT), a branch of immunotherapy, offers a promising treatment for chronic viral infections and malignant diseases such as cancer [1]. This innovative approach involves the autologous or allogenic transplant of immune cells into the patient’s body.

Biosimilars in the United States 2023–2027

whitePaper | January 31, 2023

The first biosimilar approved under the abbreviated pathway established by the Biologics Price Competition and Innovation Act launched in the U.S. in 2015.